Journal article
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing
W Schmiegel, RJ Scott, S Dooley, W Lewis, CJ Meldrum, P Pockney, B Draganic, S Smith, C Hewitt, H Philimore, A Lucas, E Shi, K Namdarian, T Chan, D Acosta, S Ping-Chang, A Tannapfel, A Reinacher-Schick, W Uhl, C Teschendorf Show all
Molecular Oncology | WILEY | Published : 2017
Open access
Abstract
An accurate blood-based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti-EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood-based RAS mutation testing is a viable alternative to standard-of-care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAMing (beads, emul..
View full abstractGrants
Funding Acknowledgements
Funding for the collection of samples in Australia was made possible by grants from the CSIRO, the Laby Foundation, and Therapeutic Innovation Australia. Financial support for this study in Germany was provided by a grant (PURE) from the Ministry of Science, North Rhine-Westphalia, Germany. This study was cooperatively funded by Sysmex Inostics and Merck KGaA. Drs Wolff Schmiegel and Rodney Scott are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.